Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer
- 1 July 2009
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 4 (7), 809-815
- https://doi.org/10.1097/jto.0b013e3181a94af4
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Detection ofEGFRGene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction AssayClinical Cancer Research, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancerNature Clinical Practice Oncology, 2005
- EGFR Mutation Status in Japanese Lung Cancer Patients: Genotyping Analysis Using LightCyclerClinical Cancer Research, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004